购物车
- 全部删除
- 您的购物车当前为空
Murlentamab (GM102) 是一种人源化抗 AMHRII 抗体。Murlentama 具有潜在的抗肿瘤活性,可诱导巨噬细胞介导的抗体依赖的细胞介导的细胞毒性作用 (ADCC)。Murl可通过募,集、活化T细胞激发促炎和抗肿瘤内环境。Murlentama 通过促进幼稚的巨噬细胞定向,促进肿瘤相关巨噬细胞 (TAM) 重编程来发挥抗肿瘤活性。
为众多的药物研发团队赋能,
让新药发现更简单!
Murlentamab (GM102) 是一种人源化抗 AMHRII 抗体。Murlentama 具有潜在的抗肿瘤活性,可诱导巨噬细胞介导的抗体依赖的细胞介导的细胞毒性作用 (ADCC)。Murl可通过募,集、活化T细胞激发促炎和抗肿瘤内环境。Murlentama 通过促进幼稚的巨噬细胞定向,促进肿瘤相关巨噬细胞 (TAM) 重编程来发挥抗肿瘤活性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 2,520 | 现货 | |
5 mg | ¥ 6,570 | 现货 | |
10 mg | ¥ 8,860 | 现货 | |
25 mg | ¥ 12,900 | 现货 | |
50 mg | ¥ 17,700 | 现货 |
产品描述 | Murlentamab (GM102) is a humanized anti-AMhRII antibody. Murlentama has potential antitumor activity that induces macrophage-mediated antitumor-dependent cell-mediated cytotoxic effects (ADCC). Murl can stimulate the pro-inflammatory and anti-tumor internal environment by recruiting, collecting and activating T cells. Murlentama exerts antitumor activity by promoting naive macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming. |
体内活性 | 在体内实验中,Murlentamab(20 mg/kg;静脉注射;每周两次;持续4周)在小鼠肝癌患者衍生的异种移植模型(PDX)[2]中抑制肿瘤生长。 |
别名 | 莫伦妥单抗, GM102, 3C23K |
分子量 | 144.56 kDa |
CAS No. | 2058047-65-5 |
存储 | store at low temperature | store at -80°C | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容